Objective: Adrenomedullin is a potent hypotensive, natriuretic and diuretic peptide that is coexpressed in the heart with its receptor, suggesting that it may have localized actions as a modulator of cardiac function. Although expression of adrenomedullin is upregulated in the pathological heart, its cardiac function has not been clearly elucidated and it is not known whether this represents a common feature of cardiac hypertrophy, nor whether this is restricted to cardiac myocytes. We have determined the direct effects of hypertrophic agents on cardiomyocyte adrenomedullin gene expression and peptide secretion and have examined the effects of adrenomedullin on biochemical markers of cardiomyocyte hypertrophy. Methods: Regulation of adrenomedullin expression and its effects on the hypertrophic response were studied in cultured rat neonatal ventricular cardiomyocytes. Results: Incubation with phenylephrine or endothelin for 48 h led to a hypertrophic response with an associated fivefold stimulation of ANP gene expression. In contrast, adrenomedullin mRNA was inhibited by 30-50% in response to phenylephrine or endothelin-mediated hypertrophy, and this was associated with a 35-45% reduction in 21 secretion of immunoreactive adrenomedullin. Phorbol ester mediated activation of protein kinase C and increasing intracellular Ca with ionomycin led to significant downregulation of adrenomedullin gene expression in cardiomyocytes. Co-incubation with 100 nM adrenomedullin for 48 h inhibited phenylephrine-induced cardiomyocyte hypertrophy as determined by protein:DNA ratio. Adrenomedullin partially blocked phenylephrine-mediated transcriptional activation of ANP and MLC-2 reporter gene expression in cardiomyocytes and this effect was mimicked by 2 mM forskolin, suggesting that this response was mediated via the activation of adenylate cyclase. Conclusion: These data demonstrate that the cardiomyocyte adrenomedullin gene is repressed by phenylephrine or endothelin-mediated hypertrophy. The inhibitory effects of adrenomedullin on the cardiomyocyte hypertrophic response suggests that this peptide acts as a regulated autocrine or paracrine modulator of cardiomyocyte function and that downregulation of adrenomedullin expression may play a role in induction and maintenance of cardiomyocyte hypertrophy.
Introduction
(ir)-AM has been found in human plasma, with significantly elevated levels that increase in proportion to clinical Adrenomedullin (AM) is a vasoactive peptide hormone severity in hypertensive [3] and congestive heart failure that has been shown to have potent hypotensive actions in patients [4, 5] . Immunocytochemical staining of human a variety of species [1] . In addition to its vascular effects, heart tissue showed that ir-AM is expressed in caradministration of AM has natriuretic and diuretic actions diomyocytes [5] and in addition, ir-AM has been shown to [1] , as well as direct actions on the heart [2] , suggesting be released into the coronary sinus in response to myocarthat AM represents an important hormone involved in dial ischemia, suggesting that such damage results in regulation of cardiovascular physiology. Immunoreactive release of AM from the heart [6] . High expression of AM mRNA and ir-AM has also been demonstrated in vascular endothelium and smooth muscle cells [1] , indicating that cells other than cardiomyocytes may produce AM in the accordance with the Australian Code of Practise for the heart, and raising the possibility that these non-myocardial Care and Use of Animals for Scientific Purposes as cells may additionally contribute to the overall cardiac described [16] . Following initial digestion with 0.1% expression of AM. Animal models have demonstrated that collagenase for 15 min at 378C, ventricles were washed in expression of AM can be upregulated in the heart in some dissociation buffer (calcium-free Dulbecco's phosphate models of hypertension, cardiac hypertrophy and cardiac buffered saline containing 1 mM MgSO ) and single cell 4 ischemia. Aortocaval shunt-induced volume overload preparations were then prepared by multiple 5-min incubacaused sustained elevation of AM mRNA and ir-AM tions with 0.08% trypsin and 0.01% DNase. Cells were peptide levels in rat LV [7] , while pressure overload then pre-plated in 100-mm culture dishes at 378C for 30 hypertrophy induced by monocrotaline [7] or aortic bandmin to remove the majority of fibroblasts. MC were ing [8] had no effect on LV AM mRNA. Experimental removed, counted and plated at an initial density of 750 2 ischemic heart failure in rats also causes a marked and cells / mm for 18 h in DMEM containing 10% FCS15% prolonged upregulation of AM expression, both within and horse serum, 0.1 mM bromodeoxyuridine (BdU), and outside the infarcted region of the myocardium [9] .
penicillin-streptomycin-fungizone solution (1:100 dilution, A number of studies have indicated that factors such as CSL, Parkville, VIC, Australia). MC were then washed in angiotensin II, endothelin, and insulin-like growth factor serum-free DMEM containing 0.1 mM BdU, 10 mg / ml can be activated within the heart and are likely to play an bovine transferrin (Sigma) and 2.5 U / ml human insulin autocrine / paracrine role in the establishment of car-(Novo Nordisk Pharmaceuticals, Australia), incubated in diomyocyte hypertrophy and progression to heart failure this medium for a further 48 h, and experiments were [10] [11] [12] . Adrenomedullin binding sites are abundant in performed by incubating cells in the same medium without heart [13] , and we have previously shown that adrenoBdU. Phenylephrine-hydrochloride (PE) and propmedullin receptor genes are expressed in cardiac myocytes ranololol-hydrochloride (PRO) were purchased from [14] . Taken together, the localised expression of adrenoSigma Chemicals and were used at final concentrations of medullin and its receptor strongly suggest that this peptide 25 mM and 1 mM, respectively. In all experiments using may function as an intracardiac regulator of myocyte PE, PRO was included to block b-adrenergic receptors. function. This notion is supported by studies demonstrating Human endothelin-1 (ET) was obtained from Auspep that exogenously administered AM inhibits angiotensin (Parkville, VIC, Australia) and rat adrenomedullin was 14 II-stimulated [ C]phenylalanine incorporation in neonatal purchased from Phoenix Pharmaceuticals (Belmont, CA, cardiomyocyte cultures, and in addition, blocking endogen-USA) and were used in culture experiments at the conous AM action with a monoclonal anti-AM antibody centrations indicated. Phorbol-12-myristate-13-acetate enhances the effects of angiotensin II [15] .
(PMA) and ionomycin were both purchased from CalDespite in vivo evidence that AM can be upregulated biochem and were dissolved in DMSO. during cardiac hypertrophy and the progression to heart failure, whether or not these changes are specific to the 2.2. RNA preparation and ribonuclease protection cardiomyocyte and the mechanisms involved in regulating analysis its expression are not known. In the present study, we have used cultured neonatal cardiomyocytes to directly deterFollowing incubation with test substances, medium was mine whether AM expression is regulated by agents known aspirated from MC cultures, the cells washed with phosto induce a hypertrophic phenotype and have also dephate buffered saline and total RNA isolated as previously termined the effects of exogenous AM on the car- and were beating synchronously. Associated with these washed 24 h post-plating with DMEM with no additives changes in cellular morphology was a significant increase and then transfected with 0.5 mg DNA and 1.5 ml Tfx-50 in cellular protein and total RNA, indicative of a hy-(Promega) in 400 ml DMEM for 1 h. Transfection medium pertrophic response (data not shown). was overlaid with 1 ml DMEM containing 0.1 mM BdU,
In addition to changes in cellular morphology and 10 mg / ml bovine transferrin and 2.5 U / ml human insulin increased biosynthesis of both RNA and protein, levels of and MC were incubated for a further 24 h. Medium was ANP mRNA were also assessed in MC cultures as an then replaced with DMEM containing 10 mg / ml bovine indicator of cardiomyocyte hypertrophy (Fig. 1B) . In transferrin, 2.5 U / ml human insulin and the appropriate ventricular MC cultures incubated in the presence of PE or test substances as indicated. Transcriptional activity of the ET for 48 h, ANP mRNA was elevated 4-5-fold above ANP and myosin light chain 2 (MLC-2) promoters were control levels (Con, 2668; PE, 11366; ET, 13065 amol / measured using a plasmid containing a 700 base-pair mg RNA (Fig. 1A) . Using a different AM mRNA probe (Waters, MA, USA) with 80% methanol10.1% trifluorocomplimentary to 225 nucleotides of exon 4 only, it was acetic acid as eluting solvent and peptide extracts were similarly shown that AM mRNA was downregulated |5-lyophilized and reconstituted in radioimmunoassay buffer fold in hypertrophied MC following 48 h stimulation with for determination of immunoreactive (ir)-AM concentra-PE (Fig. 1C) . Furthermore, RT-PCR using primers spantion as described previously [17] . The DNA content of ning exon 1-exon 4 of the rat AM sequence confirmed that each well was determined [20] as an indicator of MC PE led to downregulation of full length AM mRNA number in each experiment and was used to normalize transcripts, while ANP primers demonstrated upregulated ir-AM secretion data.
ANP mRNA in the same samples (Fig. 1D) . Release of ir-AM from cardiomyocyte cultures was 2.5. Statistical analysis measured by specific radioimmunoassay following 48 h incubation with or without hypertrophic agents. Control For all multi-group comparisons, data were analyzed by cardiomyocytes actively secreted ir-AM into the medium one-way ANOVA followed by Fisher's PLSD for post hoc (116622 pg / mg DNA over a 48 h period), and peptide comparisons. Student's t-test was used for comparisons release was significantly inhibited in MC that had been between two groups. All data are presented as incubated in the presence of either PE or ET ( To test whether the downregulation of AM mRNA in To directly determine the influence of hypertrophy on hypertrophied MC may be due to alterations in transcript cardiomyocyte AM expression, MC cultures were treated stability potentially related to AU rich motifs in the 39 tail for 48 h with the alpha adrenergic (a-AR) receptor agonist of the AM mRNA, MC were treated for 48 h with PE after phenylephrine (PE) or endothelin-1 (ET), which are well which actinomycin D (2 mg / ml) was added to the cultures to arrest gene transcription. Prior to the addition of did not change after acute transcriptional arrest with actinomycin D, AM mRNA expression was downregulated actinomycin D, AM mRNA decayed rapidly in control to |15% of control levels in MC treated with PE for 48 h MC, with an estimated half-life of 53 min. Despite the (Fig. 2) . Although the level of GAPDH mRNA expression attenuated expression in PE-treated MC, AM mRNA Table 1 was characterised by a 1. the control of either the MLC-2 or ANP promoters. Basal transcriptional activity of the MLC-2 or the ANP promoter decayed in a similar fashion to control cells, with an constructs was not significantly altered after 48 h incubaestimated half-life of 61 min (Fig. 2) . tion in the presence of 100 nM AM (Fig. 4B and C Incubation with PE (24 h) led to an eightfold increase in contacts and were spontaneously beating. Associated with ANP-Luc activity which was inhibited by |40% in the this PMA-induced hypertrophic response, AM mRNA presence of 100 nM AM (Fig. 4D) . Coincubation of expression was reduced by 50% (P,0.001) relative to cardiomyocyte cultures with low dose forskolin (0.1 mM) control cells (Fig. 3A) . Cardiomyocytes incubated with the had no effect, however, 2 mM forskolin blocked PE-
21
Ca ionophore ionomycin (500 nM) for 18 h displayed stimulated ANP-Luc activity to a similar extent as 100 nM increased spontaneous contractions and a small but signifi-AM suggesting that the inhibitory effects of AM may be cant (20% lower than control; P,0.01) decrease in AM mediated via the activation of cAMP. mRNA transcript levels (Fig. 3A) . As an internal control, expression of ANP mRNA was determined in RNA extracted from the same cultures. PMA led to a significant 4. Discussion 21 fivefold increase in ANP mRNA levels while the Ca ionophore led to a small twofold increase in the mean level Since its discovery in 1993, AM has been shown to have of ANP mRNA that did not reach statistical significance a range of biological effects including vasodilation, nat- (Fig. 3B) . riuresis and diuresis [1] , suggesting that AM may play a similar role to ANP in regulating cardiovascular responses.
AM inhibits cardiomyocyte hypertrophy and
The sustained upregulation of ANP gene expression in transcriptional activity of MLC-2 and ANP promoters ventricular cardiomyocytes is a consistent marker of hypertrophy in response to a wide variety of agents both in We have previously demonstrated that cardiac myocytes vivo and in vitro [21] . In the present study, we have shown express receptors for AM [14] , suggesting that locally that AM mRNA expression is downregulated in hypersecreted AM may play an autocrine or paracrine role in trophied cardiomyocytes, suggesting that these two genes regulating cardiomyocyte function. We therefore deterare differentially expressed and regulated in carmined the effects of exogenously administered AM on diomyocytes. The relatively low level of cardiac expresvarious parameters of the cardiomyocyte hypertrophic sion of AM and the colocalization of AM receptors in response. The overall hypertrophic growth response of cardiomyocytes [14] is consistent with this peptide having cardiomyocytes was determined by measuring proteinlocalised autocrine / paracrine effects. :DNA ratio 48 h post-treatment with PE in the absence or Both a-AR and ET-1 receptors mediate hypertrophic presence of AM (Fig. 4A ). Although AM alone had no signalling in cardiomyocytes via coupling to Gaq which in 21 significant effect, PE-mediated cardiomyocyte hypertrophy turn leads to PKC activation, alterations in Ca signalling and activation of mitogen activated protein kinase contrast to MLC-2 and ANP, however, the hypertrophic (MAPK) pathways [22] . Direct activation of PKC with response to ET or PE in cultured MC caused significant PMA leads to hypertrophic growth of cardiomyocytes [23] downregulation of AM mRNA and ir-AM secretion. The relatively few downregulated genes have been described. neonatal cardiomyocyte AM expression in vitro, in vivo Like AM, the cardiomyocyte sarcoplasmic reticulum studies in adult rats show differential effects on cardiac 21 Ca -ATPase (SERCA2) gene has been shown to be AM expression. Whether this reflects differences between downregulated by hypertrophic agents such as endothelin neonatal and adult cardiomyocytes or merely the cumulain a PKC-dependent manner [25, 26] , suggesting that the tive measurement of AM expression in multiple cell types AM and SERCA2 genes may be repressed during carin whole heart is not clear. Volume overload induced by diomyocyte hypertrophy in a similar manner. Although the aortocaval shunt causes sustained elevation of AM mRNA precise molecular mechanisms have not been fully eluciand ir-AM peptide levels in rat LV [7] , while monodated, there is evidence to suggest that PMA-induced crotaline-induced pressure overload hypertrophy [7] or mRNA destabilization may in part be responsible for aortic banding [8] had no effect on LV AM mRNA. Taken SERCA2 mRNA downregulation [26] . AM mRNA trantogether, these data suggest that the cardiac AM gene is scripts contain multiple AU-rich sequences that may be not upregulated as part of the hypertrophic phenotype per involved in mRNA destabilization, however, AM mRNA se and that its induction is dependent upon the etiology of half-life was unchanged following PE-induced hyperthe hypertrophy. Consistent with this, it was shown that trophy, suggesting that transcriptional repression may be acute pressure overload produced in rats by infusion of the major mechanism involved in downregulating AM arginine vasopressin for 2 h caused increased ventricular mRNA levels. In mouse C3H10T1 / 2 fibroblasts, transcripexpression of AM mRNA that was independent of tion of the AM gene is downregulated by Myc-mediated myocyte hypertrophy [29] . On the other hand, ventricular repression via an initiator element (INR) in the AM AM gene expression is consistently induced in the failing promoter [27] . Since c-myc gene expression is rapidly heart [5, 8, 9, 30] , suggesting AM gene activation as veninduced in cardiomyocytes in response to a-AR activation tricular dysfunction progresses. Conflicting data have been [28] , it is possible that this might represent a mechanism presented regarding the precise cellular localization of for transcriptional repression of the AM gene.
these changes however, with increased immunocytochemiDespite the clear inhibitory effects of hypertrophy on cal staining of ir-AM shown in cardiac myocytes [5] and microvascular endothelial cells [9] of the failing heart. Thus it is likely that AM expression may be regulated in multiple cell populations in the pathological heart, and that overall cardiac AM levels do not necessarily reflect expression in cardiac myocytes. The heart has a high density of AM binding sites [13] and putative AM receptor genes are expressed in cardiomyocytes [14] , implying that these cells are direct targets of AM action. Consistent with a previous study demonstrating that AM inhibits angiotensin II-stimulated 14 [ C]phenylalanine incorporation in neonatal cardiomyocytes [15], we have shown that AM can block PE-mediated cardiomyocyte hypertrophy as determined by inhibition of increases in cellular protein:DNA ratio. In addition to its effects on cellular hypertrophy, AM partially blocked the PE-stimulated transcription of two genes (ANP and MLC-2) that are well-established markers of the cardiomyocyte hypertrophic phenotype [21] .
The dose-dependent accumulation of cAMP in cardiomyocytes in response to AM has been described [31, 32] , suggesting that elevated levels of cAMP may play a role in the antihypertrophic effects of AM. Consistent with this, receptor-independent activation of adenylate cyclase with 2 mM forskolin led to similar inhibitory effects on PE-stimulated ANP gene transcription. Although the present data provide evidence for AM-mediated inhibitory effects on several parameters of the cardiomyocyte hypertrophic response that may be dependent upon increased cAMP accumulation, the molecular mechanisms involved are not known. Hypertrophic signalling in cardiomyocytes appears to involve Ras-dependent activation of Raf-1 which in turn leads to activation of MAPK pathways [21] . An inhibitory role for cAMP-dependent protein kinase A has been demonstrated in several cell types that effectively blocks Ras-dependent activation of Raf-1 and subsequent activation of downstream MAPK [33] . Though not established in the cardiomyocyte, inhibitory PKA-dependent phopshorylation of Raf-1 could account for some of the antihypertrophic effects of increased intracellular cAMP. In addition, it has been proposed that cAMP may have either positive or negative effects on cardiomyocyte ANP secretion that are related to 21 its effects on Ca transients and cellular contractile state [34] . While low doses of forskolin (0.1 mM) were shown 21 to increase cardiomyocyte Ca transients, contractile frequency and ANP secretion, higher doses of forskolin also relate to the concentration of AM used. 
